$7 biotech firm just unlocked FDA fast-track approval
|
|
|
The single most profitable sector for AI outside of pure computing is healthcare diagnostics.
|
|
Stock #5 in our November report has built an AI algorithm that detects aggressive cancers up to two years before human radiologists can. It trades under $8.
|
|
They just received an unannounced FDA Breakthrough Device designation, fast-tracking their commercial launch to 5,000+ hospitals.
|
|
They charge a recurring, per-scan licensing fee, and their first commercial revenue report drops in less than two weeks.
|
|
[Expose the Medical AI Breakout Ticker]
|
|
|
|
|
|
|
|
Questions or concerns about our products? Email support@ragingbull.com / 1-800-380-7072
|
|
© Copyright 2022, RagingBull
|
|
|
| |
|
DISCLAIMER: This entity is owned by RagingBull LLC (RB). Full disclaimer https://ragingbull.com/disclaimer/. We are a financial publisher, not a registered investment advisor. Our content is for informational purposes only and should not be considered personalized investment advice. All trading involves substantial risk of loss and you may lose some or all of your invested capital. Past performance does not guarantee future results.
|
|
*Sponsored content: This email may contain affiliate links, as identified by language such as “together with,” “In partnership with, “sponsored by,” etc. This means if you click their link, we may earn a commission at no extra cost to you. We are not responsible for any content hosted on third-party sites or your experience with third-party advertisers. It is the third party's responsibility to ensure compliance with applicable laws. We may hold positions in securities discussed and may trade without notice. We make no guarantees or warranties about what is advertised and have no fiduciary duty to subscribers. Always consult a qualified financial professional before making investment decisions.
|
|
|
|
|
|
|
|
|
|
|
|
|
© 2026 RagingBull All-Access
|
|
62 Calef Hwy. #233
Lee, NH 03861, United States
|
|
Unsubscribe
|
|
|
|
|
|
|
|
Tidak ada komentar:
Posting Komentar